NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Residual disease in the DCVax-l trial.

Remember, the easier tumors to resect are not the ones DCVax-l works best on. Instead, mesenchymal tumors are more infiltrative and tend to spread out in various directions. Mesenchymal tumors are probably why there are so many partial resections in the DCVax-l trial.

That’s in part confirmed, imho, by the NYAS DCVax slide deck, because, for overall survival at five years, DCVax-l proved statistically superior to the external control arm in treating patients with significant residual disease.

Equally important, but under appreciated, overall survival at five years for DCVax-l treating patients with significant residual disease, was equal to DCVax-l treating minimum residual disease patients. Both have essentially 13% five year survival, and both have almost 11% patients at risk — at five years.

This then logically disproves EX’s assertion that DCVax-l did not really beat the external significant residual control arm, because the treatment arm supposedly had better resections.